A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria:

• Life expectancy at least 12 weeks

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Measurable disease according to Response Evaluation criteria in Solid Tumors (RECIST) Version 1.1

• Histologically confirmed locally advanced, recurrent, or metastatic incurable solidtumor malignancy

• Tumor Specimen availability

Exclusion Criteria:

• Pregnant or breastfeeding or intention of becoming pregnant during the study orwithin 4 months after the final dose of RO7501275, or 4 months after the final doseof pembrolizumab, or 5 months after the final dose of atezolizumab

• Any anti-cancer therapy, whether investigational or approved, includingchemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiationof study treatment

• Active hepatitis B or C or tuberculosis

• Positive test for human immunodeficiency virus (HIV) infection

• Acute or chronic active Epstein-Barr virus (EBV) infection at screening

• Administration of a live, attenuated vaccine (e.g., FluMist) within 4 weeks beforefirst RO7502175 infusion

• Symptomatic, untreated, or actively progressing central nervous system (CNS)metastases

• Active or history of autoimmune disease

• Prior allogeneic stem cell or organ transplantation